| Year |
Citation |
Score |
| 2014 |
Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Human Gene Therapy. Clinical Development. 25: 16-27. PMID 24649838 DOI: 10.1089/humc.2013.201 |
0.378 |
|
| 2014 |
Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1048-55. PMID 24572293 DOI: 10.1038/Mt.2014.22 |
0.386 |
|
| 2013 |
Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. Plos One. 8: e81768. PMID 24312353 DOI: 10.1371/Journal.Pone.0081768 |
0.429 |
|
| 2013 |
Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, Friedman GK. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatric Blood & Cancer. 60: 45-52. PMID 22408058 DOI: 10.1002/Pbc.24117 |
0.324 |
|
| 2012 |
Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM. Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. International Journal of Breast Cancer. 2012: 628697. PMID 23346408 DOI: 10.1155/2012/628697 |
0.432 |
|
| 2012 |
Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, Gillespie GY, Whitley RJ. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. Journal of Virology. 86: 5304-13. PMID 22379082 DOI: 10.1128/Jvi.06998-11 |
0.522 |
|
| 2012 |
Gillory L, Haas M, Friedman G, Megison M, Stewart J, Parker J, Markert J, Gillespie G, Beierle E. Genetically Engineered Herpes Simplex Virus Expressing IL-12 Suppresses Murine Neuroblastoma Tumor Growth Journal of Surgical Research. 172: 196. DOI: 10.1016/J.Jss.2011.11.176 |
0.475 |
|
| 2011 |
Lin WJ, Zheng X, Lin CC, Tsao J, Zhu X, Cody JJ, Coleman JM, Gherzi R, Luo M, Townes TM, Parker JN, Chen CY. Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection. Molecular and Cellular Biology. 31: 3196-207. PMID 21690298 DOI: 10.1128/Mcb.05073-11 |
0.41 |
|
| 2011 |
Parker JN, Zheng X, Luckett W, Markert JM, Cassady KA. Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents. Molecular Pharmaceutics. 8: 44-9. PMID 21142023 DOI: 10.1021/Mp100230Y |
0.466 |
|
| 2011 |
Gaston DC, Whitley RJ, Parker JN. Engineered herpes simplex virus vectors for antitumor therapy and vaccine delivery Future Virology. 6: 321-340. DOI: 10.2217/Fvl.11.4 |
0.475 |
|
| 2011 |
Gillory LA, Haas MC, Friedman GK, Stewart JE, Parker JN, Markert JM, Gillespie GY, Beierle EA. Combination treatment with genetically altered oncolytic herpes simplex virus and low-dose irradiation inhibits neuroblastoma tumor growth Journal of the American College of Surgeons. 213: S76. DOI: 10.1016/J.Jamcollsurg.2011.06.178 |
0.47 |
|
| 2010 |
Cassady KA, Parker JN. Herpesvirus Vectors for Therapy of Brain Tumors~!2009-12-17~!2010-01-07~!2010-06-17~! The Open Virology Journal. 4: 103-108. PMID 20811578 DOI: 10.2174/1874357901004030103 |
0.428 |
|
| 2009 |
Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM. Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2042. PMID 27964649 DOI: 10.1200/Jco.2009.27.15_Suppl.2042 |
0.437 |
|
| 2009 |
Shah AC, Parker JN, Shimamura M, Cassady KA. Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response. Viruses. 1: 510-22. PMID 21994558 DOI: 10.3390/V1030510 |
0.658 |
|
| 2009 |
Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 558-69. PMID 19560745 DOI: 10.1016/J.Nurt.2009.04.011 |
0.481 |
|
| 2009 |
Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, Yancey Gillespie G. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. Journal of Neuro-Oncology. 95: 199-209. PMID 19521665 DOI: 10.1007/S11060-009-9926-0 |
0.359 |
|
| 2009 |
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 199-207. PMID 18957964 DOI: 10.1038/Mt.2008.228 |
0.482 |
|
| 2007 |
Parker SD, Rottinghaus ST, Zajac AJ, Yue L, Hunter E, Whitley RJ, Parker JN. HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice. Vaccine. 25: 6764-73. PMID 17706843 DOI: 10.1016/J.Vaccine.2007.06.064 |
0.42 |
|
| 2007 |
Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Therapy. 14: 1045-54. PMID 17429445 DOI: 10.1038/Sj.Gt.3302942 |
0.688 |
|
| 2007 |
Guffey MB, Parker JN, Luckett WS, Gillespie GY, Meleth S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Therapy. 14: 45-56. PMID 16990846 DOI: 10.1038/Sj.Cgt.7700978 |
0.594 |
|
| 2006 |
Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. Oncolytic HSV-1 for the treatment of brain tumours. Herpes : the Journal of the Ihmf. 13: 66-71. PMID 17147910 |
0.333 |
|
| 2006 |
Shah AC, Price KH, Parker JN, Samuel SL, Meleth S, Cassady KA, Gillespie GY, Whitley RJ, Markert JM. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. Journal of Virology. 80: 7308-15. PMID 16840311 DOI: 10.1128/Jvi.00725-06 |
0.673 |
|
| 2006 |
Parker JN, Pfister LA, Quenelle D, Gillespie GY, Markert JM, Kern ER, Whitley RJ. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine. 24: 1644-52. PMID 16243413 DOI: 10.1016/J.Vaccine.2005.09.051 |
0.442 |
|
| 2005 |
Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-Oncology. 7: 213-24. PMID 16053696 DOI: 10.1215/S1152851705000074 |
0.527 |
|
| 2005 |
Kriesel JD, Spruance SL, Prichard M, Parker JN, Kern ER. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. The Journal of Infectious Diseases. 192: 156-61. PMID 15942905 DOI: 10.1086/430612 |
0.362 |
|
| 2005 |
Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Therapy. 12: 359-68. PMID 15678154 DOI: 10.1038/Sj.Cgt.7700784 |
0.533 |
|
| 2001 |
Markert JM, Parker JN, Gillespie GY, Whitley RJ. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes : the Journal of the Ihmf. 8: 17-22. PMID 11867012 |
0.397 |
|
| 2000 |
Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 97: 2208-13. PMID 10681459 DOI: 10.1073/pnas.040557897 |
0.447 |
|
| 1998 |
Steenbergen RD, Parker JN, Isern S, Snijders PJ, Walboomers JM, Meijer CJ, Broker TR, Chow LT. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of human papillomavirus type 16- and 18-transfected human keratinocytes. Journal of Virology. 72: 749-57. PMID 9420282 DOI: 10.1128/Jvi.72.1.749-757.1998 |
0.313 |
|
| Show low-probability matches. |